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Background: The modest benefits of gemcitabine (dFdC) therapy in patients with pancreatic ductal adenocarcinoma (PDAC) are
well documented, with drug delivery and metabolic lability cited as important contributing factors. We have used a mouse model
of PDAC: KRASG12D; p53R172H; pdx-Cre (KPC) that recapitulates the human disease to study dFdC intra-tumoural metabolism.
Methods: LC-MS/MS and NMR were used to measure drug and physiological analytes. Cytotoxicity was assessed by the
Sulphorhodamine B assay.
Results: In KPC tumour tissue, we identified a new, Kennedy pathway-linked dFdC metabolite (gemcitabine diphosphate choline
(GdPC)) present at equimolar amounts to its precursor, the accepted active metabolite gemcitabine triphosphate (dFdCTP).
Utilising additional subcutaneous PDAC tumour models, we demonstrated an inverse correlation between GdPC/dFdCTP ratios
and cytidine triphosphate (CTP). In tumour homogenates in vitro, CTP inhibited GdPC formation from dFdCTP, indicating
competition between CTP and dFdCTP for CTP:phosphocholine cytidylyltransferase (CCT). As the structure of GdPC precludes
entry into cells, potential cytotoxicity was assessed by stimulating CCT activity using linoleate in KPC cells in vitro, leading to
increased GdPC concentration and synergistic growth inhibition after dFdC addition.
Conclusions: GdPC is an important element of the intra-tumoural dFdC metabolic pathway in vivo.
Gemcitabine (dFdC) has been the drug used most frequently for
patients with pancreatic ductal adenocarcinoma (PDAC) for
several decades, but its modest effects are well documented, with
median survival of only 6.7 months (Von Hoff et al, 2013).
Research has focused on drug delivery and metabolic lability as the
potential causes for the poor response rates. Metabolic activation of
dFdC in cells is initiated by deoxycytidine kinase (dCK) to give the
monophosphate. Further sequential phosphorylation yields the
diphosphate and triphosphate, both responsible for the cytotoxic
effects of the drug. Gemcitabine diphosphate (dFdCDP) inhibits
ribonucleotide reductase, which catalyses formation of deoxynu-
cleotide triphosphates required for DNA synthesis. When
incorporated into DNA, gemcitabine triphosphate (dFdCTP)
terminates DNA chain elongation (Huang et al, 1991; Plunkett
et al, 1995). 20,20-difluorodeoxyuridine (dFdU) has been considered
to be the major inactive metabolite of dFdC; however, its
triphosphorylated form dFdUTP may contribute to cytotoxicity
(Veltkamp et al, 2008). Metabolism-based approaches to improve
dFdC efficacy are ultimately aimed at increasing the amount of
dFdCTP and have thus far manipulated nodes in the drug’s
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metabolic pathway likely to favour dFdCTP formation, such as
reducing cytidine deaminase-mediated dFdU formation (Beumer
et al, 2008; Costanzi et al, 2011; Tibaldi et al, 2011). However, such
approaches will be informed by knowledge of intra-tumoural
metabolism of the drug that has been limited by the scarcity of
tissue specimens from patients.
To gain insight into dFdC pharmacology, we recently developed
an assay to measure dFdC and its metabolites in tumour tissue
from the KRASG12D; p53R172H; pdx-Cre (KPC) genetically
engineered mouse model of PDAC (Bapiro et al, 2011). Using
the same assay, the likelihood of further metabolism of dFdCTP
was also investigated, with a focus on its possible metabolism by
enzymes in the Kennedy pathway of phosphatidylcholine (PtdCho)
synthesis. The precedent for this is cytosine arabinoside (Ara-C)
(Lauzon et al, 1978a,b), the diphosphate choline metabolite of
which is thought to be formed from PtdCho and Ara-C
monophosphate, in a reversal of the reaction catalysed by
cholinephosphotransferase (CPT) (Figure 1; Kucera and Capizzi,
1992). PtdCho is a phospholipid with critical roles in lipid
membrane synthesis and signal transduction. The majority of
PtdCho is synthesised from choline via the Kennedy pathway in
three steps (Figure 1) catalysed by the enzymes choline kinase
(CK), CTP:phosphocholine cytidylyltransferase (CCT) and CPT.
We hypothesised that dFdCTP could compete with the physiolo-
gical Kennedy pathway substrate cytidine triphosphate (CTP) for
the enzyme CCT, resulting in the formation of gemcitabine
diphosphate choline (GdPC) in place of the normal physiological
metabolite CDP choline.
Here, we report the identification of GdPC as a major dFdC
metabolite in murine PDAC tumour tissue from the KPC
genetically engineered mouse. In MIA PaCa-2 xenograft tissue
the GdPC/dFdCTP ratio was lower than in KPC PDAC tissue, and
in K8484 (KPC PDAC cell line) allograft tissue the GdPC/dFcCTP
ratio was higher than in KPC PDAC. Therefore, using these
different models of pancreatic cancer, we were able to probe the
Kennedy pathway for correlants of the observed GdPC/dFdCTP
ratios that could be important determinants of dFdC pharmaco-
kinetics and pharmacodynamics.
MATERIALS AND METHODS
Mouse studies. All mouse experiments were carried out in
accordance with the UK Animals (Scientific Procedures) Act
1986, revised by the Amendment Regulations 2012 (SI 2012/3039)
to transpose European Directive 2010/63/EU, with approval from
the local Animal Welfare and Ethical Review Body, and following
the 2010 guidelines from the United Kingdom Coordinating
Committee on Cancer Research (Workman et al, 2010).
KPC mouse model of PDAC has been described previously
(Hingorani et al, 2005; Olive et al, 2009). KPC mice develop
advanced PDAC from 2 to 3 months and have a shortened median
survival of approximately 5 months.
Enrolment of KPC mice in the study was based on tumour size,
measured by ultrasound in an axial orientation using the Vevo 770
System (Visual Sonics, Inc., Toronto, ON, Canada) (Cook et al,
2008; Olive et al, 2009). Mice with mean PDAC tumour diameters
of 6–9mm were enrolled.
K8484 is a cell line that was established from a KPC PDAC
tumour as described previously (Olive et al, 2009). Control
littermates of KPC mice, p53R172H; Pdx1-Cre (PC) female mice
were used in this study to transplant 1 106 K8484 cells in PBS
subcutaneously into each flank. The mice were dosed with dFdC
when the tumours reached at least 200mm3. Three mice were used
per time point (two tumours per mouse).
Subcutaneous xenografts of MIA PaCa-2 cells were established
by implanting 5 106 cells in the flank of female 9-week-old
BALB/c nude mice (Charles River UK Ltd., Margate, UK). The
mice were dosed with dFdC when the tumours reached at least
300mm3. At least three mice were used per time point.
dFdC HCl (Tocris Bioscience, Bristol, UK) was dissolved in
sterile 0.9% saline to 20mgml 1 and then used to dose the mice.
For PK studies, the mice were killed at fixed time points after a
single dose of 100mg kg 1 IP dFdC, and plasma and tumour were
then snap-frozen. For efficacy studies, mice were dosed twice per
week with 100mg kg 1 IP dFdC , as used in previous therapeutic
studies (Frese et al, 2012; Courtin et al, 2013).
Identification of GdPC. To identify GdPC, an LC-MS/MS
method for the physiological metabolite CDP choline (C0256,
Sigma Aldrich Co Ltd., Dorset, UK) based on the method by
(Desoubzdanne et al, 2010) was developed. A Sciex 4000 Q trap
mass spectrometer (AB Sciex UK Ltd., Warrington, UK) fitted with
a Turbo ionspray source at 500 1C operated in positive mode was
used. Quantitative data acquisition was done using the software
Analyst ver 1.4.2 (Ab Sciex UK Ltd.). Given the similarities in
structure between CDP choline and GdPC (Figure 2A and B), their
chromatographic properties were also expected to be similar.
PDAC tissue, obtained from a mouse 2 h after IP injection of dFdC
(100mg kg 1), was precipitated using 100% acetonitrile. After
centrifugation, the supernatant was transferred to a clean tube and
evaporated to dryness. The residue was reconstituted in 75%
acetonitrile and injected into the mass spectrometer. An enhanced
product ion scan for the expected precursor ion for GdPC (m/z
509) was run (under the same conditions as for the multiple
reaction monitoring experiment for CDP choline). The spectra
obtained were compared with those of CDP choline to aid
identification of GdPC.
Quantitation of dFdC, dFdU, dFdCTP, GdPC, Cytidine, CTP
and CDP choline by LC-MS/MS in tumour tissue and cell
extracts. GdPC (Cat. no. G305015) was synthesised by Toronto
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Figure 1. The Kennedy pathway of phosphatidylcholine synthesis and
breakdown to phosphatidic acid. PLA2/A1, phospholipase A2/A1; LPL,
lysophospholipase. (Kennedy and Weiss, 1956; Fagone and Jackowski,
2013).
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Research Chemicals (Toronto, ON, Canada) while CTP and
cytidine were purchased from Sigma Aldrich Co Ltd. The analytes
in tumour tissues were quantified essentially as previously
described (Bapiro et al, 2011). Minor modifications included
addition of MRM transitions for GdPC (509–184.05), CTP
(484–111.91), cytidine (244–112.04) and CDP choline (489.1–184.05).
In addition, the mobile phase gradient starting conditions were
modified to 98% ammonium acetate pH 10 and 2% acetonitrile
instead of 95% and 5%, respectively. To obtain cell extracts from
culture in vitro, cells were harvested by trypsinisation and counted.
The cells were then washed with ice-cold PBS, and pellets were
obtained by centrifugation at 20 000 g for 20min. Ice-cold 60%
methanol (volume adjusted for number of cells) containing
tetrahydrouridine (25 mgml 1) was added to cell pellets and
vortexed vigorously. The cell methanol mixture was incubated at
 80 1C for at least 30min and then sonicated for 10min in an
ice-bath. In all, 50ml of the cell extract was then processed as described
above for the tumour tissue. Absolute concentrations were
obtained for dFdC, dFdU, dFdCTP and GdPC, because these are
non-endogenous metabolites, and standard curves could be created
using non-dFdC-treated tissue or cell homogenates as the blank
matrix. CDP choline, CTP and cytidine were expressed as relative
concentrations (based on MS peak area ratio of analyte vs internal
standard), because these are endogenous metabolites, and so no
blank matrix was obtainable to use for standard curves.
Quantitation of phosphocholine, glycerophosphocholine and
total choline containing metabolites by NMR. In all, 25mg of
tumour tissue from untreated mice and from mice 4 h post-dFdC
(100mg kg 1) IP were homogenised in 50% acetonitrile using
a Precellys homogeniser (Stretton Scientific, Stretton, UK) in
reinforced tubes with small ball bearings (Precellys MK28-R) for
2 50 s at 5800 r.p.m. After centrifugation at 20 000 g for 20min,
the supernatant was transferred to a clean tube and evaporated to
dryness. The residue was dissolved in 0.5ml of D2O and
transferred to a 5mm standard NMR tube; 10 ml of 10mM DSS
(4,4-dimethyl-4-silapentane-1-sulphonic acid) was then added as
an external standard. The NMR tubes were then loaded onto a
600MHz Bruker Avance NMR spectrometer (Bruker UK Ltd.,
Coventry, UK). NMR data was then acquired with a water
presaturation pulse sequence. 1H NMR spectroscopic acquisition
parameters included 32k time domain data points, 512 averages,
repetition delay of 5 s and acquisition time of 2.2 s, resulting in a
total acquisition time of 1 h 2min for each spectrum. The acquired
data were Fourier transformed, phase corrected and the baseline
was corrected. We used the Bruker TOPSPIN 2.1 software for
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Figure 2. The identification of GdPC by LC-MS/MS. Chemical structures of (A) the physiological metabolite CDP choline, (B) GdPC and
(C) enhanced product ion scan spectrum of GdPC (precursor, at m/z 509) and proposed fragmentation.
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NMR spectral acquisition and processing and the NMR Suite 7.5
(Chenomx Inc., Edmonton, AB, Canada) software package for
identification and quantitation of metabolites. The DSS signal was
used to identify the chemical shifts of metabolites and to estimate
the absolute metabolite concentrations.
Cell culture. The K8484 cell line was maintained in DMEM (D6429,
Sigma Aldrich Co Ltd.) containing 5% FBS (10270-098, Life
Technologies Ltd., Paisley, UK). MIA PaCa-2 cells were obtained
from the European Collection of Cell Cultures (Public Health
England, Salisbury, UK, authenticated by STR genotyping) and
maintained in DMEM containing 10% FBS. Gemcitabine (3259,
Tocris Bioscience) was dissolved in DMSO; linoleate (L8134, Sigma
Aldrich Co Ltd.) and 6-diazo-5-oxo-L-norleucine (DON, D2141
Sigma Aldrich Co Ltd.) were dissolved in sterile water. Experiments
assessing the effect of DON on dFdC metabolism were carried
out in media lacking glutamine (D5671, Sigma Aldrich Co Ltd.).
Growth-inhibition assays were carried out using the sulphorhodamine
assay, and subsequent synergy calculations were done as previously
described (Lin et al, 2012).
Effect of CTP on GdPC formation in tumour homogenate. KPC
PDAC tissue homogenised in 0.1 M Tris-Cl buffer pH 7.4 (1:4) was
used as the source of CCT enzyme. The reaction mixture in a final
volume of 200 ml consisted of tissue homogenate (10 ml),
magnesium chloride (8mM), EDTA (1.8mM), phosphocholine
(1mM) and Tris-Cl buffer pH 7.4 (0.1 M). The reaction was started
by adding dFdCTP (200 mM) and incubated at 37 1C for 30min,
and the reaction was stopped by adding 200 ml of ice-cold
acetonitrile (100%). The effect of CTP (200mm) on GdPC
formation was assessed by adding CTP to the reaction mixture.
A control sample was incubated under the same conditions, with
dFdCTP added after stopping the reaction. After centrifugation at
20 000 g for 20min, the supernatant was transferred to a clean tube
and evaporated to dryness. The residue was reconstituted in 100 ml
water, and 15 ml was used for quantitation of GdPC using the
LC-MS/MS method mentioned above.
Statistical analysis. Statistical analyses were performed using the
GraphPad Prism version 6 (GraphPad Software Inc., La Jolla, CA,
USA). A one-way ANOVA was used followed by Holm–Sidak’s
multiple comparison posttest.
RESULTS
Identification and quantitation of GdPC. LC-MS/MS analysis
was performed on homogenate from a KPC tumour taken 2 h after
a single dose of dFdC. An enhanced product ion spectrum for
GdPC of the expected precursor ion m/z 509 yielded spectra
adequate for a definitive identification, which was aided by
comparison with that of CDP choline m/z 489.2, given their
similar structures (Figure 2A–C). The fragment ions at m/z 184.1,
166 and 125 are characteristic of the phosphocholine moiety
(Vaezian et al, 2010; Lattanzio et al, 2009; Hayashi et al, 1989;
Antonopoulou et al, 2002). A sample of GdPC was then custom-
synthesised for use in standard curves for subsequent quantifica-
tion of GdPC in tumour homogenates.
PDAC models. In order to investigate the significance of GdPC,
we next assessed concentrations of dFdCTP and GdPC in in vivo
models of pancreatic cancer. dFdC shows little efficacy in KPC
mouse PDAC tumours (Olive et al, 2009). The intra-tumoural
concentrations of dFdC, dFdU, dFdCTP and GdPC were measured
in KPC mice after administration of 100mg kg 1 dFdC, and
samples were collected at 1, 2, 4, 6 and 10 h with at least five
animals per time point. GdPC and dFdCTP exhibited similar
concentration time profiles in KPC mice, and maximum
concentrations were observed at about 2 h (Figure 3A). Peak
dFdCTP was 6.1±3.9 pmolesmg 1 tissue and remained detectable
at 10 h in only one of the samples. Peak GdPC was
7.2±3.8 pmolesmg 1 at 2 h and below the level of quantification
by 10 h. The concentration time profile for dFdC and dFdU in the
same samples is shown in Supplementary Figure S1A. We then
investigated whether GdPC could be detected in other in vivo
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Figure 3. dFdC metabolism and efficacy in PDAC models in vivo. Tumour GdPC and dFdCTP concentrations after IP administration of dFdC
(100mgkg 1) with results expressed as mean±s.e.m. in (A) KPC mice, with seven mice per time point except 10-h time point where five mice
were used. We have recently shown the dFdCTP concentration time profile (Neesse et al, 2013). (B) In K8484 (KPC PDAC cell) allograft-bearing
mice, both analytes were below the limit of quantitation (BLQ) at the 24-h time point with three mice per time point except at the 1-h time
point where n¼ 2; and (C) in MIA PaCa-2 xenograft-bearing mice, GdPC was BLQ at the 24-h time point with at least three mice per time point
(results are the mean±s.e.m.). (D) The effect of dFdC on tumour volumes (mean±s.e.m.) with time in days after tumour implantation in K8484
allografts, which were dosed on days 8, 11, 15, 18, 22 and 25 (n¼ 10 per group), and (E) tumour volumes in MIA PaCa-2 xenografts dosed with
dFdC on days 16, 19, 23 and 26 (n¼10 per group).
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pancreatic cancer models used in our laboratory – first, in
subcutaneous allografts of a cell line K8484 derived from a KPC
PDAC tumour. This allograft model responds very well to dFdC
(Figure 3D). For PK analysis, K8484 cells were transplanted
subcutaneously into syngeneic Kraswt; p53R172H; Pdx1-Cre (PC)
mice, and once the tumours had grown sufficiently, a single dose of
dFdC (100mg kg 1, IP) was administered. Tumour tissue samples
were collected at 0.25, 0.5, 1, 2, 4 and 24 h and were used to
quantify dFdC and metabolites. To our surprise and in contrast to
results in the KPC mouse tumour tissue, GdPC was the
predominant metabolite, with at least a four-fold higher AUC
than dFdCTP (Figure 3B). The peaks were maximal at 1 and 2 h for
dFdCTP and GdPC, respectively, and both metabolites were
below the limit of quantification at 24 h. Of note, the absolute
dFdCTP concentrations in the K8484 allograft (peak 3.0±2.0
pmolesmg 1) were lower than those in the KPC model, but the
GdPC concentrations were much higher (peak 16.4±4.1pmolesmg 1).
The concentration time profile for dFdC and dFdU in the same
tumours is shown in Supplementary Figure S1B.
While mindful of the complexities of comparing different
species, we have also assessed amounts of dFdCTP and GdPC in
the MIA Paca-2 xenograft, another model that is sensitive to
growth inhibition by dFdC (Figure 3E). In MIA PaCa-2 xenograft
PK studies, after a single dose of dFdC, dFdCTP was the
predominant metabolite over GdPC (Figure 3C), the opposite
result to that seen in K8484 allografts. The peak concentration of
dFdCTP, at 4 h, was 10.2±5.0 pmolesmg 1 and that of GdPC was
1.6±0.5 pmolesmg 1. Again, both metabolites were below the
limit of quantification at 24 h. The concentration time profile for
dFdC and dFdU in the same tumours is shown in Supplementary
Figure S1C. Representative H&E images of tumour sections from
each of the three models are shown in Supplementary Figure S2.
We next investigated whether differences in Kennedy pathway
intermediates could explain the differences in amounts of dFdCTP
and GdPC observed in the different in vivo models of pancreatic
cancer.
Comparison of Kennedy pathway intermediates in tumour
tissue from in vivo PDAC models. 1H HR NMR spectroscopy
was used to measure concentrations of Kennedy pathway
intermediates phosphocholine, glycerophosphocholine and total
choline-containing metabolites in tumour homogenates from KPC
PDAC, K8484 allografts and MIA PaCa-2 xenografts taken before
and 4 h after IP administration of dFdC (100mg kg 1)
(Supplementary Figure S3). No differences were observed in
the concentrations of the Kennedy pathway metabolites between
samples from dFdC-dosed and untreated mice in each group.
The only significant difference was in the phosphocholine/
glycerophosphocholine ratio, when dFdC-dosed K8484 allografts
were compared with dFdC-dosed MIA Paca-2 xenografts
(Supplementary Figure S3C). Using our LC-MS/MS assay, we
then quantified relative levels of CDP choline and CTP in
tumour homogenates of mice from the three different
models taken 2 h after administration of dFdC. Although no
significant difference was observed in the relative concentrations
of CDP choline (Figure 4A), both CTP and cytidine exhibited
an inverse correlation with the concentration of GdPC
(Figure 4B and D). The K8484 allografts had the highest
concentrations of GdPC and the lowest concentrations of CTP,
while MIA PaCa-2 xenografts had the lowest GdPC but
highest CTP concentration. We hypothesised that the inverse
correlation between CTP and GdPC might be caused by
inhibition of GdPC formation by CTP. Therefore an in vitro
assay was established to measure formation of GdPC using a
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homogenate of KPC PDAC tissue as an enzyme source and
dFdCTP as the substrate, and this assay was used to assess the
effect of CTP. CTP was found to be an inhibitor of GdPC
formation (Figure 4E). Treating K8484 cells in vitro with the
CTP synthase inhibitor DON resulted in 450-fold reduction in
CTP levels, accompanied by a 15-fold increase in the GdPC
concentration (Supplementary Figure S4), confirming that CTP
inhibits GdPC formation.
Investigation of whether GdPC contributes to dFdC
anti-tumour activity. Comparison of the GdPC/dFdCTP profiles
in the three in vivo models (Figure 3) with the relative efficacy of
dFdC in those models suggests a role for GdPC in dFdC anti-
tumour activity assessed on the basis of effect on tumour volume.
After adding dFdC (100 nM) to K8484 cells in vitro, in sharp
contrast to the results with K8484 allografts in vivo, it was apparent
that dFdCTP (Figure 5A) was the predominant metabolite rather
than GdPC (Figure 5B), and in other PDAC cell lines incubated
with dFdC the in vitro GdPC concentration was rarely above the
lower limit of quantification (data not shown). Attempts to assess
the cytotoxicity of GdPC by adding increasing concentrations of
the compound to cells in culture failed, because it was degraded to
dFdC in the culture medium (even in the absence of cells) – the
highest concentration used, 300 nM of GdPC, was almost
completely converted to dFdC within 24 h of incubation at
37 1C (data not shown). Thus, manipulation of the intracellular
generation of GdPC was felt to be the only feasible approach to
assess its impact on cytotoxicity. Linoleic acid has been shown to
activate CCT and synthesis of PtdCho (Mallampalli et al, 1994;
Burkhardt et al, 1988), so we assessed the effects of adding linoleic
acid on the cytotoxic effects of dFdC in K8484 cells using an 8 8
concentration combination assay, incubating for 72 h. We observed
significant synergistic effects with Emax of 99% growth inhibition at
10 nM dFdC and 170 mM linoleate, compared with a prediction of
57% growth inhibition if the effect of the two drugs were additive
in accordance with the Bliss Additivity model (Figure 5C). Shorter
incubations with 170 mM linoleate were used to assess its effect on
dFdC (100 nM) metabolism: dFdCTP concentrations were unaf-
fected by linoleate (Figure 5A), but there was a 10-fold increase in
GdPC concentration at 2.5 h, and it continued to be higher over
10 h (Figure 5B). Thus linoleate increased the cellular GdPC
concentration after dFdC administration and enhanced dFdC
cytotoxicity synergistically.
DISCUSSION
For the past two decades, dFdC alone or in combination has been
the standard of care for PDAC (reviewed in Michl and Gress,
2013), with few new therapeutic advances resulting in improved
survival. One exception is FOLFIRINOX, a combination devoid of
dFdC which recently showed increased survival in PDAC (Conroy
et al, 2011) but is too toxic to be used routinely in the majority of
patients. dFdC combinations continue to be important, as
exemplified by results of the recently completed phase III trial of
a nab-paclitaxel/dFdC combination (Von Hoff et al, 2013). Part of
the mechanism of efficacy of this combination may be the ability
of nab-paclitaxel to enhance dFdC efficacy via modulation of its
metabolism by cytidine deaminase (Frese et al, 2012). We have
now used the KPC model to shed new light on the intra-tumoural
metabolism of dFdC with the hope of uncovering novel metabolic
targets with potential to improve the drug’s efficacy. We have
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Figure 5. The effect of the combination of linoleate and gemcitabine in K8484 cells. The timecourse of production of (A) dFdCTP and (B) GdPC in
K8484 cells grown in DMEM supplemented with 5% FBS and treated over 10 h with linoleate (170 mM) and dFdC (100 nM). Results are the
mean±s.d. of three replicates. (C) Effect on growth of K8484 cells using the sulphorhodamine B cytotoxicity assay, exposed to an 8 8
combination of linoleate and dFdC for 72 h. The left panel shows the experimental data (mean of three independent experiments, each done in
triplicate) and shows the percentage of growth inhibition compared with DMSO control. A Bliss additivity model built from the experimental single
agent data shows the predicted growth inhibition if the combination were additive (middle). The right panel shows the difference values after
subtracting the predicted values from the experimental data, with difference values of 425 considered to show synergy (in blue).
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shown here that the Kennedy pathway-linked GdPC is a major
metabolite of dFdC in vivo. The metabolic pathway by which it is
formed is shown in Figure 6.
Compounds analogous to this CDP choline metabolite have
been shown to be formed from compounds with similar
structures to dFdC, including 2’,3’-dideoxycytidine (zalcitabine),
zebularine and arabinofuranosylcytosine (ara-C) (Lauzon et al,
1978a,b; Rossi et al, 1999; Ben-Kasus et al, 2005). An unidentified
metabolite X, making up 2.8% of total dFdC, was reported
in Chinese Hamster Ovary cells in studies using radiolabeled
dFdC (Heinemann et al, 1988), which they suggested could be the
‘CDP choline analogue similar to that found in cells treated with
ara-C’. As shown by our in vitro studies, in cultured cells,
dFdCTP is the predominant metabolite rather than GdPC, with
GdPC concentrations rarely above the limit of quantification,
which explains why dFdC metabolism experiments conducted in
cultured cells would probably fail to detect GdPC as an important
metabolite.
The three in vivo PDAC models showed different intra-
tumoural GdPC/dFdCTP ratios that inversely correlated with
CTP concentrations, a feature that was explained by the inhibition
of GdPC formation by CTP observed in vitro using tumour
homogenates. It is, however, not clear why there are differences in
the CTP concentrations. An important difference of the models
used relates to their stromal component. The fact that we are able
to detect GdPC in both subcutaneous xenografts (which have little
stroma) and the authochthonous PDAC in KPC mice (with
extensive stroma) suggests that its production is not specific to
tumour stroma.
The greater efficacy of dFdC in the K8484 allografts and the
predominance of GDPC over dFdCTP in this model implicated
GdPC as a possible cytotoxic metabolite, so that mechanism was
investigated in cells in vitro.
Ideally, cytotoxic effects of GdPC would have been easily studied
by adding increasing concentrations to cultured cells; however, this
was not possible because of the instability of GdPC in culture
medium, coupled with its chemical structure (charged choline and
phosphate groups at physiological pH) which is likely to prevent it
from crossing the plasma membrane. Generating the metabolite
intracellularly offered a solution to this problem, and this was
achieved by combining dFdC with linoleic acid, which is known to
activate CCT, resulting in synergistic cytotoxicity. The mechanism
of the observed synergistic cytotoxicity accompanying the
increased GdPC concentration is not clear. The equivalent
metabolite of ara-C at very high concentrations (400mM) is
thought to cause excessive formation of PtdCho resulting in cell
lysis (Daly et al, 1990) but is unlikely to be the case in our study
because a 1000-fold lower concentration of dFdC was used.
The clinical relevance of our findings is supported by reports of
an on-going clinical trial suggesting better outcomes in
pancreatic cancer patients treated with dFdC and the fish oil
formulation Lipidem (B. Braun Melsungen AG, Melsungen,
Germany), one of whose major constituents is linoleic acid
(Arshad et al, 2013a,b). We believe that Lipidem may promote
formation of the active form of CCT and might also increase
tumoural concentrations of GdPC.
In conclusion, we have established GdPC as an important
element of the dFdC metabolic pathway in tumour tissue in mouse
models of PDAC and shown that its formation may contribute to
dFdC cytotoxicity.
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